2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studies
2021
Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting?
Saffarzadeh AG, Canavan M, Resio BJ, Walters SL, Flores KM, Decker RH, Boffa DJ. Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting? JTO Clinical And Research Reports 2021, 2: 100201. PMID: 34590044, PMCID: PMC8474436, DOI: 10.1016/j.jtocrr.2021.100201.Peer-Reviewed Original ResearchLong-term mortality riskStage III NSCLCLow dosePreoperative settingMortality riskHigh doseRadiation doseClinical stage III patientsNational Cancer Database dataStage III lung cancerStage III patientsUse of surgeryLength of stayGy of radiationCox proportional hazardsComparative effectiveness analysisOptimal radiation doseSingle-dose strategyLong-term survivalRadiation dosesLogistic regression modelsDefinitive chemoradiotherapyN2 patientsNonsurgical patientsPerioperative outcomes